Press Releases September 3, 2026 04:05 PM

Lifecore Biomedical to Participate at CPHI Global Conference

Lifecore Biomedical announces participation at CPHI Global Conference to engage with clients on injectable CDMO services.

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
LFCR

Lifecore Biomedical, a Nasdaq-listed contract development and manufacturing organization specializing in sterile injectable pharmaceuticals, will participate in the CPHI Global Conference in Milan from October 6-8, 2026. Company leaders will meet prospective customers to discuss process development and manufacturing services for injectable programs.

Lifecore Biomedical to Participate at CPHI Global Conference
LFCR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Lifecore will attend the CPHI Global Conference to connect with prospective clients and showcase its injectable product capabilities.
  • The company emphasizes its expertise in sterile injectable formulations including syringes, vials, and cartridges, serving biopharmaceutical and biotechnology sectors.
  • Lifecore is recognized as a leading manufacturer of injectable-grade hyaluronic acid with over 40 years of industry experience.

CHASKA, Minn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the CPHI Global Conference. The conference will take place October 6-8, 2026, in Milan, Italy.

Details regarding Lifecore’s participation are as follows:

  • CPHI Global Conference
    Details: Lifecore leaders, including Mark DaFonseca, chief commercial officer, and business development directors Mary Evelyn Hudson, Edward Purell, and Dan Dennehy, will host meetings with prospective customers to discuss process development and manufacturing services for injectable programs.
    Booth number: 8J60
    Conference Dates: October 6-8, 2026
    Location: Fiera Milano, Italy

If you are interested in meeting with Lifecore during this event, please reach out to us at: [email protected].

About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.

Contact Information:
Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
[email protected]

Jennifer Arcure (Media)
917-603-0681
[email protected]

Lifecore Biomedical
Ryan D. Lake (CFO)
952-368-6244
[email protected]


Risks

  • Participation in industry conferences does not guarantee new contracts or business growth, maintaining uncertainty in revenue impact.
  • Competition in the CDMO sector from other global manufacturers may affect Lifecore's ability to secure new clients or contracts.
  • Potential global supply chain or regulatory challenges in manufacturing injectable pharmaceuticals could impact project timelines and costs.

More from Press Releases

Verizon Waives Charges for Hurricane Lowell, Prepares Network in Hawai'i Sep 5, 2026 Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen Sep 4, 2026 Grupo Aeroportuario del Pacifico Reports a Passenger Traffic Increase in August 2026 of 0.5% Compared to 2025 Sep 4, 2026 Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference Sep 4, 2026 Alpha Compute Corp. Market Update Sep 4, 2026